The Effect of Informative Letters on the Prescription and Receipt of Seroquel

How to cite

Sacarny, Adam; Yokum, David. 2015. "The Effect of Informative Letters on the Prescription and Receipt of Seroquel." AEA RCT Registry. AEARCTR-0000729. https://doi.org/10.1257/rct.729-5.1

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Adam Sacarny* , David Yokum

* Primary investigator

Registry ID
AEARCTR-0000729
DOI
https://doi.org/10.1257/rct.729-5.1
First registered
Last updated
Status
Completed
Trial dates
2015-04-20 – 2017-07-01
Countries
United States of America ()
Registry record
http://www.socialscienceregistry.org/trials/729

Abstract

Abusive prescribing exposes patients to unnecessary health risks and results in wasteful public expenditures. This study will evaluate an innovative approach to fighting abusive prescription: sending letters to suspected inappropriate prescribers warning them that they are outliers compared to their peers and have been flagged for review. The study will target high prescribers of Seroquel (Quetiapine), an atypical antipsychotic. Using claims data, we will assess the effect of the letters on prescribing of Seroquel, receipt of Seroquel by patients, substitution behavior by prescribers and patients, and health outcomes of patients.

Intervention

Placebo Arm: The placebo arm receives a letter unrelated to Seroquel. The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
Interventional Arm: The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals. The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.

Experimental design

An analysis was conducted to identify outlier prescribers of Seroquel in the Medicare Part D events file. This analysis identified a group of prescribers, and they were then randomly allocated to a treatment or a control group. The approach is explained in more detail in the study protocol document.

Design details

Randomization method
Randomization done by computer (in Stata)
Randomization unit
The prescriber
Clusters
5,055
Observations
5,055
Arms
2,527 allocated to treatment arm 2,528 allocated to control (placebo) arm
Primary outcomes
The primary outcome of the study is the 30-day equivalent prescribing of Seroquel treatments over the 9 months following the initial sending of the letters. Prescribing is defined as the total "days supply" of Seroquel attributed to the prescriber, expressed in "30-day equivalents" i.e. divided by 30. This outcome and the secondary outcomes are described in greater detail in the study prespecification document.

Cited by

No citation data available for this registration yet.

Keywords